Enanta Pharma (ENTA) Reports Positive Topline Results from Phase 2 SPRINT Trial of EDP-235
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street lower on AI spending jitters; oil prices rebound
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Brent hits five-month high on escalating Middle East conflict
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| ENANTA PHARM (NASDAQ: ENTA) | Delayed: 11.43 +0.12 (1.06%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $11.31 | 52 Week High | $34.49 | |||
| Open | $11.31 | 52 Week Low | $20.39 | |||
| Day High | $11.58 | P/E | N/A | |||
| Day Low | $11.09 | EPS | $-3.18 | |||
| Volume | 8,447 | |||||
